Completed PHASE2 INTERVENTIONAL 2-arm NCT00393263

Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus

A Double-Blind, Parallel-group Trial of Topical Pimecrolimus Cream 1% (Elidel®) Versus Clobetasol 0.05% Cream for the Treatment of Vulvar Lichen Sclerosus

Sponsor: Center for Vulvovaginal Disorders

Conditions Lichen Sclerosus

Interventions clobetasol 0.05% cream pimecrolimus and clobetasol

Updated 7 times since 2017 Last updated: May 8, 2014 Started: Oct 31, 2006 Primary completion: Oct 31, 2009 Completion: Oct 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00393263, this PHASE2 trial focuses on Lichen Sclerosus and remains completed. Sponsored by Center for Vulvovaginal Disorders, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Center for Vulvovaginal Disorders
Novartis

Data source: Center for Vulvovaginal Disorders

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Washington D.C., United States